close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Clinical Insights

The efficacy and safety of viscosupplements have been well documented. Less well-understood, however, may be how SYNVISC® compares with other viscosupplements.

Viscosupplements for Osteoarthritis Knee Pain:
A meta-analysis evaluating magnitude of pain relief

The efficacy and tolerability of viscosupplements for the treatment of osteoarthritis knee pain has been well established in a number of clinical trials. However, until recently, no analysis existed that provided physicians with insight into the magnitude of pain relief that viscosupplements provide.


Download PDF

The Magnitude of Pain Relief with SYNVISC® (hylan G-F 20) as Demonstrated in 3 Well-Controlled Trials

Included in guidelines for the treatment of osteoarthritis (OA) knee pain 1 , 2 viscosupplementation has become an established therapy in the United States. Somewhat less established, however, may be the criteria that physicians must consider when determining which viscosupplement to use. These criteria may include efficacy and safety profiles, clinical experience, and treatment schedule.


Download PDF

Clarifying Tolerability Issues in Viscosupplementation for Osteoarthritis Knee Pain

Numerous well-controlled clinical trials, as well as a retrospective chart review, have shown that treatment for osteoarthritis (OA) knee pain with SYNVISC (hylan G-F 20) has a low incidence of local adverse events (AEs)—an incidence consistent with current product labeling.1 , 2 , 3 , 4 However, the frequency, severity, and management of these events have been a subject of some discussion among clinicians.


Download PDF



Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)